The Unfinished Science of Boxed Drug Warnings - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Incomplete Understanding of Boxed Warnings for Medications

  • By

  • John G. Rizk

  • John C. Lewin

  • May 22, 2026

Share

Objective:

To examine the impact of the FDA's boxed warning on montelukast prescribing practices.

Key Findings:
  • 30% relative reduction in montelukast initiation following the boxed warning.
  • 5% relative reduction in montelukast prevalence post-warning.
  • Absolute changes in prescribing were small, with a decline of 1 to 2 fewer new prescriptions per 1000 patients.
Interpretation:

Limitations:
  • Limited awareness among clinicians and patients may have reduced the warning's impact.
  • Uncertainty regarding the causal association between montelukast and neuropsychiatric events may hinder prescribing changes.
Conclusion:

Original Source(s)

The Unfinished Science of Boxed Drug Warnings

  • by John G. Rizk, John C. Lewin

  • May 22, 2026

Related Content

Measles Renews Focus on Vaccine Waivers

“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”

In Vitro Performance of Valved Holding Chambers in Paediatric Asthma Controller Therapy

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.